$17.43 0.10 (+0.58%)
2/9/2010 4:00 PM

Amylin Pharmaceuticals, Inc. (AMLN)

CAPS Rating: 3 out of 5

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

Current Price $17.43 Mkt Cap $2.47B
Open $17.68 P/E Ratio 0.00
Prev. Close $17.33 Div. (Yield) N/A (N/A)
Daily Range $17.29 - $17.79 Volume 1,610,618
52-Wk Range $7.89 - $19.99 Avg. Daily Vol. 0

AMLN News and Commentary

View All AMLN News and Commentary

Caps

How do you think AMLN will perform vs the S&P 500?

Add Stock to Watchlist

All Members

352 Outperform
53 Underperform
 

All-Star Members

102 Outperform
14 Underperform
 

Wall Street

6 Outperform
5 Underperform
 

Top AMLN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

EmmyKaye (75.16)
Submitted January 16, 2009

Based on the statements made by the President of the company during the bio-tech conference conference in San Francisco, the FDA advised the company that they could use the data base on the one million patients already on Byetta, to meet the criteria… More

Dobbes (63.67)
Submitted January 11, 2010

Amylin, where to begin.

How about with their flagship product Byetta. Its an injection to treat diabetes that just can't capture enough market to make AMLN profitable. Management is doing a poor job. Things are so bad they recently lost a… More

AMLN VS S&P 500 (SPY)

Fools bullish on AMLN are also bullish on:

Fools bearish on AMLN are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about AMLN.

Recs

0
Member Avatar gangsterchen (< 20) Submitted: 2/1/2010 10:06:41 PM : Outperform Start Price: $17.72 AMLN Score: +0.23

long acting diabetes drug will be approved soon.

Recs

0
Member Avatar bikoman (25.24) Submitted: 1/23/2010 9:17:08 PM : Outperform Start Price: $17.19 AMLN Score: +4.03

up

Recs

0
Member Avatar PenicillinG (77.43) Submitted: 1/13/2010 9:52:28 AM : Underperform Start Price: $16.15 AMLN Score: -13.79

I don’t believe Byetta LAR will be approved in March;
1. The manufacturing process uses a double emulsion (water in oil in water) and suffers from poor yield, highly variable results and inconsistent drug product performance.
2. Because of number 1, I believe efficacy (while statistically significant) will be inferior to the BID dosage form (and competitive products).
3. The FDA scrutinizes the safety of all sustained release injectable drugs to a much higher standard than those of oral drugs.

Leaderboard

Find the members with the highest scoring picks in AMLN.

Score Leader

teamtec

teamtec (83.39) Score: +152.27

The Score Leader is the member with the highest score across all their picks in AMLN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
teamtec 83.39 11/24/2008 Outperform 1Y $6.09 +186.21% +33.94% +152.27
embodiedheart 94.09 12/2/2008 Outperform 5Y $6.26 +178.43% +29.50% +148.94
ajsiegel 98.50 12/3/2008 Outperform 1Y $6.35 +174.33% +32.31% +142.02
GimmeGoldSlv < 20 11/12/2008 Outperform NS $7.39 +135.86% +27.07% +108.79
lemsilogram < 20 11/17/2008 Outperform 3Y $7.49 +132.71% +27.51% +105.20 1 Comment
eazydoes 93.85 12/8/2008 7/16/2009 Outperform 1Y $7.99 +118.15% +21.68% +96.47
EmmyKaye 75.16 12/9/2008 Outperform 3Y $8.87 +96.51% +21.73% +74.77 1 Comment
Turbolover 82.54 4/3/2009 Outperform 5Y $8.87 +96.51% +30.36% +66.15
SimonSaysSell 38.28 4/6/2009 Outperform 3M $9.37 +86.02% +29.94% +56.08 1 Comment
cschier < 20 4/6/2009 Outperform 5Y $9.37 +86.02% +29.94% +56.08

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackBarclaysCap 94.50 11/25/2009 Outperform NS $13.36 +30.46% -3.41% +33.87
TrackCanaccord 86.15 1/28/2009 Underperform NS $10.80 +61.39% +26.29% -35.10
TrackJimCramer < 20 10/23/2008 Underperform 3W $11.34 +53.70% +19.97% -33.73
TrackLazardCapit < 20 9/2/2008 Outperform NS $22.40 -22.19% -14.98% -7.21
TrackSoleil 93.91 8/27/2008 Underperform NS $23.81 -26.80% -13.27% +13.53
TrackIcahn 32.10 5/29/2008 Outperform 1Y $31.68 -44.98% -20.02% -24.96 5 Comments
TrackBMOCapital 91.22 4/22/2008 Underperform NS $27.41 -36.41% -19.46% +16.95
TrackCanaccord 86.15 2/12/2008 Underperform NS $30.04 -45.24% -21.64% +23.60 10/7/2008 @ $16.45
TrackRWBaird 87.00 1/15/2008 Outperform NS $35.50 -37.38% -8.56% -28.82 8/27/2008 @ $22.23
TrackZacks 62.21 12/13/2007 Underperform 3M $38.87 -65.73% -33.71% +32.02 10/20/2008 @ $13.32 1 Comment
TrackLehmanBros 85.06 11/1/2007 Underperform NS $44.00 -28.98% -9.36% +19.62 5/28/2008 @ $31.25
TrackEdwardOwens 98.91 9/30/2007 Outperform NS $50.00 -65.14% -26.38% -38.76 2 Comments
TrackJefferies 82.08 9/26/2007 Outperform NS $49.99 -45.69% -10.14% -35.55 6/9/2008 @ $27.15
TrackZacks 62.21 9/11/2007 Underperform 3M $48.72 -6.36% +1.48% +7.84 10/19/2007 @ $45.62 1 Comment
TrackLazardCapit < 20 9/10/2007 Outperform NS $49.24 -48.80% -9.03% -39.78 3/3/2008 @ $25.21
TrackJimCramer < 20 7/30/2007 Outperform 3W $47.15 -75.95% -36.81% -39.14 10/23/2008 @ $11.34
TrackStanfordRes 85.54 7/24/2007 Outperform NS $44.08 -34.87% -16.87% -18.00 8/19/2008 @ $28.71
TrackGaryBSmith 74.46 5/25/2007 Outperform 3W $44.91 -61.19% -25.27% -35.92
TrackWRHambrecht 64.18 3/13/2007 Outperform NS $38.19 -54.36% -18.98% -35.38
TrackLeerinkSwan 92.83 2/5/2007 Outperform NS $39.00 -77.26% -43.47% -33.79 4/7/2009 @ $8.87
TrackBroadpoint.AmTech 76.97 1/31/2007 Underperform NS $38.93 -55.23% -20.10% +35.13
TrackFBRCapitalM 79.87 1/31/2007 Outperform NS $39.05 -34.98% -10.47% -24.51 6/30/2008 @ $25.39
TrackLazardCapit < 20 8/11/2006 Underperform NS $42.31 -5.32% +14.02% +19.34 4/13/2007 @ $40.06
TrackJimCramer < 20 2/27/2006 Underperform 3W $43.97 +7.23% +13.48% +6.25 7/31/2007 @ $47.15

Featured Broker Partners